Stalfort John A III
SEC insider (Form 3/4/5 filer). CIK 0001709418. Director at Acumen Pharmaceuticals, Inc. (ABOS) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 3, 2026. Located in DALLAS, TX.
Companies Stalfort John A III has filed insider reports for
- Acumen Pharmaceuticals, Inc. (ABOS): Director
- Taysha Gene Therapies, Inc. (TSHA): Director
- Verrica Pharmaceuticals Inc. (VRCA): Director
Stalfort John A III
CIK: 0001709418
Transaction Breakdown
Open Market Buys (P)1 (16.7%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)1 (16.7%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 3, 2026ABOS
Acumen Pharmaceuticals, Inc.
AwardDirect35.5K shares- - Jun 1, 2026TSHA
Taysha Gene Therapies, Inc.
AwardDirect21.3K shares- - Jun 4, 2025ABOS
Acumen Pharmaceuticals, Inc.
AwardDirect12.8K shares- - Jun 2, 2025TSHA
Taysha Gene Therapies, Inc.
AwardDirect56.6K shares- - Nov 26, 2024VRCA
Verrica Pharmaceuticals Inc.
GiftDirect50K shares- - Nov 22, 2024VRCA
Verrica Pharmaceuticals Inc.
PurchaseDirect1.1M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  ABOS Acumen Pharmaceuticals, Inc. | Award | 35,500 | - | $0 | Direct |
| Jun 1, 2026 |  TSHA Taysha Gene Therapies, Inc. | Award | 21,335 | - | $0 | Direct |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | Award | 12,800 | - | - | Direct |
| Jun 2, 2025 | TSHA Taysha Gene Therapies, Inc. | Award | 56,623 | - | - | Direct |
| Nov 26, 2024 |  VRCA Verrica Pharmaceuticals Inc. | Gift | 50,000 | - | $0 | Direct |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | Purchase | 1,123,595 | - | $0 | Direct |
1-6 of 6 transactions